CompoundAI integrates multi-omics data, molecular modeling, and clinical outcome prediction into a single discovery workflow - cutting the time from target to IND by half.
From target identification through clinical candidate selection - each layer informs the next, reducing the compounding uncertainty that kills most discovery programs.
Multi-omics integration across genomics, proteomics, and transcriptomics to surface biologically validated targets with disease relevance scores.
Structure-based and ligand-based design workflows. Protein structure prediction integrated with binding affinity scoring at scale.
Absorption, distribution, metabolism, excretion, and toxicity profiles predicted before synthesis - flagging liabilities early in the program.
Patient stratification models and biomarker selection to guide clinical trial design, dose selection, and endpoint definition.
Our current pipeline spans oncology, neurodegeneration, metabolic disease, and rare disease - all originated using the CompoundAI discovery platform.
First-in-class KRAS G12C inhibitor. Dose escalation in progress at 4 clinical sites. Preliminary pharmacokinetic data expected Q3 2026.
Tau aggregation inhibitor targeting early-stage Alzheimer's disease. Safety evaluation cohort fully enrolled. Data readout Q4 2026.
Novel FGF21 receptor agonist for NASH. Completing GLP toxicology studies. IND submission expected Q1 2027.
Enzyme replacement for a lysosomal storage disorder. Lead series identified via CompoundAI platform. In vitro optimization underway.
Undisclosed target in inflammatory bowel disease. Target validation complete. Hit-to-lead screening initiated.
Partner logos - image placeholders to be replaced in Artist phase
We work with pharmaceutical companies and research institutions through collaboration and licensing agreements. If you have a target or indication that could benefit from our platform, we'd like to talk.
Request a Meeting